Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.49 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19742218 | 1.00 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAKDM4EHPGD | |
| SCHEMBL29855580 | 1.00 | FOLH1 (0.49) | FOLH1NAALAD2RIMKLAKDM4EHPGD | |
| SCHEMBL29100639 | 0.86 | FOLH1 (0.46) | FOLH1NAALAD2RIMKLAKDM4EHPGD | |
| SCHEMBL23067830 | 0.82 | P2RY12 (0.38) | — | |
| SCHEMBL23067828 | 0.82 | TBXAS1 (0.38) | EGLN3 | |
| SCHEMBL8569467 | 0.82 | TBXAS1 (0.35) | EGLN3 | |
| SCHEMBL29100674 | 0.78 | HRH4 (0.49) | FOLH1NAALAD2HPGD | |
| SCHEMBL29100675 | 0.78 | HRH4 (0.49) | FOLH1NAALAD2HPGD | |
| SCHEMBL21881741 | 0.71 | CYP26A1 (0.43) | KDM4EHPGDGAA | |
| SCHEMBL4671255 | 0.71 | P2RY12 (0.35) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024023332-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2024-02-01 | — | — | WO | disclosed |
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-12-21 | — | — | US | disclosed |
| CN-113677400-B | Dual mode radiotracer and therapeutic agent that bind PSMA | 慕尼黑工业大学 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023227535-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2023-11-30 | — | — | WO | disclosed |
| EP-4282438-A1 | FUNCTIONALIZED BISAMINOTHIOL DERIVATIVES, COMPLEXES WITH THESE BISAMINOTHIOL DERIVATIVES AND USE OF SAID COMPLEXES AS DIAGNOSTICS AND THERAPEUTICS | ABX Advanced Biochemical Compounds GmbH (DE) | 2023-11-29 | — | — | EP | disclosed |
| CN-117069621-A | Dual targeting constructs affecting tumor killing | 康奈尔大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-113573743-B | Cancer diagnostic imaging agent | 慕尼黑工业大学 | 2023-11-07 | — | — | CN | disclosed |
| EP-4249456-A2 | PSMA BINDING DUAL MODE RADIOTRACER AND THERAPEUTIC | Technische Universität München (DE) | 2023-09-27 | — | — | EP | disclosed |
| EP-4249005-A2 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | Technische Universität München (DE) | 2023-09-07 | — | — | US | disclosed |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2020-07-21 | — | — | US | disclosed |
| WO-2019115547-A1 | PSMA LIGANDS FOR IMAGING AND ENDORADIOTHERAPY | Technische Universität München (DE) | 2019-06-20 | — | — | WO | disclosed |
| EP-3493856-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | Cornell University (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| EP-3474903-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | Cornell University (US) | 2019-05-01 | — | — | EP | disclosed |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | CORNELL UNIVERSITY (US) | 2019-01-15 | — | — | US | disclosed |
| WO-2018005625-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | CORNELL UNIVERSITY (US) | 2018-01-04 | — | — | WO | disclosed |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | UNIV CORNELL (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2017223357-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | CORNELL UNIVERSITY | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406847-A1 | LIGANDS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) CONTAINING HETEROAROMATIC LINKER BUILDING BLOCKS | KLK3, FOLH1, BPHL | FOLH1 2/4885NAALAD2 58/4885RIMKLA 1251/4885 |
| US-10716772-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | FOLH1 2/4885NAALAD2 393/4885RIMKLA 3072/4885 |
| US-20170368005-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | FOLH1 2/4885NAALAD2 393/4885RIMKLA 3072/4885 |
| US-20190142770-A1 | DOUBLE TARGETED CONSTRUCTS TO AFFECT TUMOR KILL | PSMA2, FOLH1, KLK3 | FOLH1 2/4885NAALAD2 393/4885RIMKLA 3072/4885 |
| US-10179117-B2 | Double targeted constructs to affect tumor kill | PSMA2, FOLH1, KLK3 | FOLH1 2/4885NAALAD2 393/4885RIMKLA 3072/4885 |
| US-20170369454-A1 | 18F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORS | PSMA3, FOLH1, PSMA1 | FOLH1 2/4885NAALAD2 114/4885RIMKLA 2244/4885 |
| US-20230277698-A1 | SILICON-CONTAINING LIGAND COMPOUNDS | KLK3, SHBG, SELPLG | FOLH1 8/4885NAALAD2 915/4885RIMKLA 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.